Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors

Overview

This study compare the efficacy of conventional photodynamic (PDD) guided transurethral bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction of bladder tumors through flexible cystoscopes.

Full Title of Study: “Is Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (LMD-BT) as Good as Conventional Inpatient PDD Guided Transurethral Tumor Resection in Patients With Low Grade Non-invasive (Ta) Bladder Tumors?”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2018

Detailed Description

A prospective randomized two-part clinical trial comprising patients with recurrent pTa low grade bladder tumors. Study objectives and purpose: – 1st Objective: To evaluate whether small pTa bladder tumours can be removed with diode laser in an outpatient department with similar efficacy as by TUR-BT resection in the operating theatre. – 2nd Objective: To evaluate the patients experience of symptoms during laser treatment in the outpatient department (OPD) using quality of life (QOL) questionnaires (symptom evaluation) and Visual Analog Scale Score (pain evaluation). – 3rd Objective: To evaluate whether patients prefer standard transurethral bladder tumor resection (TUR-BT) in the operating theatre (OT) or laser treatment in the OPD. – 4th Objective: To evaluate the safety after laser treatment in the OPD. Efficacy: – 1st Endpoint: Proportion of patients with no tumor tissue in the bladder after 4 months and 12 months. – 2nd Endpoint: Visual Analog Scale Score (pain evaluation) in patients having tumor removed by laser in the OPD. General urinary problems and QOL one week after the laser treatment. The Danish validated questionnaire (QLQ- BLS24) from EORTC will be used. – 3rd Endpoint: Patients preference for either OPD laser treatment procedure or TUR-BT in the OT as inpatient procedure. – 4th Endpoint: Character and severity of adverse events in relation to the outpatient treatment. Study Inclusion criteria: 1. Ta low grade bladder tumor recurrences 2. Up to a tumor size of 1,5 cm 3. Up to 6 tumors 4. Eligible patients for TUR-BT Exclusion criteria: 1. Patients with porphyria 2. Known hypersensitivity to Hexvix® or porfhyrins 3. Use of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa 4. Dementia 5. Macroscopic hematuria 6. Pregnant or breast feeding women 7. Expected poor compliance estimated by the investigators 8. Patients < 18 years 9. Patients who do not read or understand Danish

Interventions

  • Device: Bladder tumor resection using diathermia
    • Conventional bladder tumor resection using diathermia
  • Device: Diode laser (980 nm) tumor destruction
    • Laser mediated destruction of bladder tumors (LMD-BT)

Arms, Groups and Cohorts

  • Active Comparator: Inpatient TUR-BT
    • Transurethral bladder tumor resection in operating theatre as inpatient.
  • Experimental: laser bladder tumor destruction
    • Outpatient laser mediated destruction of bladder tumors (LMD-BT)

Clinical Trial Outcome Measures

Primary Measures

  • Tumor recurrence histological identified in biopsy obtained during cystoscopy
    • Time Frame: 4 months
    • Numbers (%) of patients vith histological proven recurrence of bladder tumor after 4 months

Secondary Measures

  • Lower urinary symptoms caused by laser treatment.
    • Time Frame: 2 weeks
    • Using the EORTC questionnaire QLQ-BLS24 the extent of symptoms are given on a unique score from 0-100, with 0 being no symptoms and 100 are worst symptoms. Mean and range score in the two arms will be compared statistically.
  • Side effects to laser treatment.
    • Time Frame: 2 weeks
    • Symptoms measured by one unique score according to the Clavien-Dindo grading system. Mean and range score in the two arms will be compared statistically.
  • Pain during laser treatment
    • Time Frame: Evaluated immediately after laser treatment
    • The patients record pain on a visual analogue scale of 0-10. Zero corresponds to no pain. Ten correspond to the worst possible pain.

Participating in This Clinical Trial

Inclusion Criteria

1. Ta low grade bladder tumor recurrences 2. Up to a tumor size of 1,5 cm 3. Up to 6 tumors 4. Eligible patients for TUR-BT in GA Exclusion Criteria:

1. Patients with porphyria 2. Known hypersensitivity to Hexvix® or porfhyrins 3. Use of concomitant anticoagulants as Marevan, Marcoumar, and Pradaxa 4. Dementia 5. Macroscopic hematuria 6. Pregnant or breast feeding women 7. Expected poor compliance estimated by the investigators 8. Patients < 18 years 9. Patients who do not read or understand Danish

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital Bispebjerg and Frederiksberg
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gregers Gautier Hermann, Consultant Urologist – University Hospital Bispebjerg and Frederiksberg
  • Overall Official(s)
    • Gregers G Hermann, DM Sc, Principal Investigator, Department of Urology, Frederiksberg hospital
  • Overall Contact(s)
    • Gregers G Hermann, DM Sc, +45 38163536, gregersgautierhermann@regionh.dk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.